ERBB2 and neoplasm: Cinrebafusp alfa, a bispecific antibody against HER2 and the co-stimulatory immune receptor 4-1BB on T cells, has shown tolerability and anti-tumor activity in a phase I trial and is currently under investigation for second-line therapy of HER2-positive (high and low) gastric cancer [88].